Clinical trials: open to volunteers, sponsored by Imperial College London
OESOPHAGO-GASTRIC CARCINOMA
Hypoxia Driven Metabolic Response in Oesophagogastric Adenocarcinoma
Oesophagogastric Cancer and Hypoxia: Oesophagogastric cancer is a significant global burden, with 1.7 million new cases per year. It is well known that survival from oesophagogastric cancer is poor.
- Trial name
- HYDRA (NCT06669663)
- Testing
- Pimonidazole hydrochloride (Hypoxyprobe™-1)
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Imperial College London
Liver Cirrhosis, Hepatocellular Carcinoma (HCC)
A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions
Liver cancer is often diagnosed too late for effective treatment. The VOCAL2 study is developing a simple, non-invasive breath test to help detect liver cancer earlier and monitor liver conditions like cirrhosis.
- Conditions
- Liver Cirrhosis, Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Cholangitis, Sclerosing
- Trial name
- VOCAL2 (NCT06864195)
- Where
- United Kingdom
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Inherited Cardiac Conditions, Cardiovascular Diseases
Inherited Cardiac cONditions In Kids
All patients with heart disease should have the opportunity to participate in research into their condition, to advance knowledge and treatment.
- Trial name
- ICONIK (NCT05158738)
- Testing
- Patients with inherited cardiac condition, onset <16 years old and Parents
- Where
- 3 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- Imperial College London
Oesophageal Adenocarcinoma, Gastric Adenocarcinoma
Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery
Oesophagogastric cancer (cancer of the gullet and stomach) is the fifth most common cancer in England and Wales with 16,000 new cases diagnosed every year. Survival rates are poor with only 15% surviving beyond 5 years.
- Trial name
- LABS (NCT06289374)
- Testing
- Biosample collection
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Imperial College London
Energy Intake, Metabolism
Identifying Wearable Biomarkers to Monitor Dietary Intake
Background: Measuring what people eat is a challenge in nutrition research. Traditional methods, like food diaries, rely on self-reporting of individuals, and suffer from poor accuracy and recall bias.
- Conditions
- Energy Intake, Metabolism, Digestion, Wearables
- Trial name
- FoodSense (NCT06398340)
- Testing
- High Calorie Meal Intervention, Low Calorie Meal Intervention
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Squamous Cell Carcinoma, Breath Test
Early Diagnosis of Upper Digestive Tract Disease
Upper digestive tract cancer (UDC) is a major disease burden worldwide encompassing all cancers involving the digestive tract (from oral cavity to duodenum).
- Conditions
- Squamous Cell Carcinoma, Breath Test, Digestive System Disease, Diagnose Disease
- Trial name
- E-DIGEST (NCT04475952)
- Where
- United Kingdom
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Chronic Cough
Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients
This study is being done in order to understand what causes people to have a chronic cough, which is defined as a cough lasting for more than 8 weeks.
- Trial name
- NCT06286163
- Where
- 2 sites in United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Volatile Organic Compounds, Microbiome
Augmented Response of Volatile Biomarkers in Assessment of Oesophagogastric Cancer (AROMA 1 / BIORESOURCE)
Cancer of the stomach and oesophagus is among the world's top five cancers. Survival rates are very poor as the disease presents late and early symptoms are non-specific.
- Conditions
- Volatile Organic Compounds, Microbiome, Microbioata, Breath Analysis
- Trial name
- NCT05412758
- Testing
- Oral Stimulant Drink
- Where
- United Kingdom
- Volunteers
- 648 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Cancer, Disease
Public Survey on Breath Testing for Health and Disease
A brief survey for the public to determine interest in health surveillance and disease detection
- Conditions
- Cancer, Disease, Health Behavior, Health Attitude
- Trial name
- NCT06081452
- Testing
- Survey
- Where
- United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Polycystic Ovary Syndrome
DAISy-PCOS Phenome Study - Dissecting Androgen Excess and Metabolic Dysfunction in Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) affects 10% of all women and usually presents with irregular menstrual periods and difficulties conceiving.
- Trial name
- DAISy-PCOS (NCT03911297)
- Testing
- Women with polycystic ovary syndrome
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Imperial College London
Cushing's Disease, Hypercortisolism
Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection
Cushing's disease is a rare condition where the body produces too much of a hormone called cortisol. Cortisol helps with metabolism, the immune system, and managing stress.
- Conditions
- Cushing's Disease, Hypercortisolism, Pituitary Adenoma, Pituitary ACTH Secreting Adenoma
- Trial name
- OPTIMAL (NCT06701838)
- Testing
- 11C-Methionine PET/CT
- Volunteers
- 15 people
- Sponsor
- Imperial College London
Rectal Cancer, Colo-rectal Cancer
Pre-therapeutic MRI Assessment of Early-Stage Rectal Cancer and Significant Rectal Polyps to Avoid Major Resectional Surgery
When a patient is diagnosed with a rectal (bowel) polyp or cancer, radiology doctors read MRI scans to describe how deeply the cancer invades into the bowel wall (this is the 'stage' of the cancer).
- Trial name
- PRESERVE (NCT04103372)
- Testing
- MRI scan, Radiologist training
- Where
- 23 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- Imperial College London
Colo-rectal Cancer
EMVI as a Determinant of Metastasis in Colorectal Cancer
Bowel cancer is the fourth most commonly occurring cancer and the second highest cause of cancer deaths in the UK. Despite advances in treatment, over 40% of patients will die within 5 years.
- Trial name
- EVIDENCE (NCT06646341)
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Imperial College London
Arrhythmia
Hearables: Ear-ECG and PPG for Detection of Cardiac Arrhythmias
The goal of this observational study is to determine the feasibility of detecting abnormal heart rhythms, known as arrhythmias, by recording Electrocardiogram (ECG) and Photoplethysmogram (PPG) waveforms from the ears in patients…
- Trial name
- NCT06667258
- Testing
- Ear ECG/PPG sensors
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Cardiovascular Diseases
Smart Wearable Insights to Prevent Exacerbations and Recurrence - Rehabilitation Study: SWIPER-REHAB
Aims of the study: To measure the rate of completion of a digital cardiac rehabilitation programme at Imperial College Healthcare NHS Trust (ICHNT) To measure the health economic impact of a digital cardiac rehabilitation…
- Trial name
- SWIPER-REHAB (NCT06011395)
- Testing
- Smartwatch, Imperial Healthy Hearts app
- Where
- United Kingdom
- Volunteers
- 1,800 people
- Sponsor
- Imperial College London
Cancer, Colorectal Neoplasms
Improving Radical Treatment Through MRI Evaluation of Pelvic Sigmoid Cancers
Patients with suspected or proven sigmoid colon adenocarcinoma, eligible for curative treatment whose MRI can be reviewed prior to surgery and has no decision regarding radical treatment are eligible.
- Conditions
- Cancer, Colorectal Neoplasms, Colon, Sigmoid, Magnetic Resonance Imaging
- Trial name
- IMPRESS (NCT02222844)
- Testing
- Preoperative MRI scan
- Where
- 16 sites in United Kingdom
- Volunteers
- 244 people
- Sponsor
- Imperial College London
Colorectal Neoplasms, Neoplasm Metastases
Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)
Eligible patients with high risk colorectal malignancy (T3/4, spread greater than 5mm, EMVI positive) will have additional surveillance of breath hold T1, T2 and DW-MRIs (no IV contrast) post surgery six monthly for three years.
- Conditions
- Colorectal Neoplasms, Neoplasm Metastases, Hepatic Neoplasms
- Trial name
- SERENADE (NCT02246634)
- Testing
- Diffusion Weighted MRI scan
- Where
- 13 sites in United Kingdom
- Volunteers
- 282 people
- Sponsor
- Imperial College London
Neoplasms, Adenocarcinoma
Beyond TME Origins
All patients with recurrent colorectal cancer in the pelvis are eligible. The original primary tumour staging scans and resected surgical specimen needs to be available.
- Conditions
- Neoplasms, Adenocarcinoma, Carcinoma
- Trial name
- NCT02292641
- Testing
- New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery
- Where
- 4 sites in Norway, United Kingdom
- Volunteers
- 383 people
- Sponsor
- Imperial College London
Cancer, Rectal Cancer
Circulating Tumour DNA (ctDNA) in Patients With Colorectal Cancer and the Relationship to Imaging Features of Extramural Venous Invasion
This study does not involve randomization or treatment. Eligible patients have colorectal adenocarcinoma with no metastases eligible for curative surgery.
- Trial name
- ctDNA (NCT02579278)
- Testing
- Blood sample (mrEMVI positive patient), Blood sample (mrEMVI negative patient)
- Where
- 3 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Imperial College London
Rectal Cancer
Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial
Open to patients undergoing any pre-operative treatment for locally advanced rectal cancer, TRIGGER is the only phase III clinical trial in the UK offering watch and wait.
- Trial name
- TRIGGER (NCT02704520)
- Testing
- High resolution MRI scan, mrTRG assessment
- Where
- 10 sites in United Kingdom
- Volunteers
- 441 people
- Sponsor
- Imperial College London